Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Slides:



Advertisements
Similar presentations
Policies and Processes for Limiting Conflict of Interest Patrick N. Breysse, PhD, CIH Johns Hopkins University Bloomberg School of Public Health Vice-Chair,
Advertisements

1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
The Pharmaceutical Industry and ICH Q9
CADTH Therapeutic Reviews
Office of New Drug Chemistry (ONDC)
Role of ERCB in Synergy and Public Involvement Synergy Alberta Conference October 28, 2008.
Produce Safety Rule Phase 2 Workgroup 1.
Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
Final Report on Process Analytical Technology (PAT) and Manufacturing Science Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science,
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Ensuring Physical Stability of Pharmaceuticals: Can/should we improve our ability to identify and prevent physical changes? Ajaz S. Hussain, Ph.D. Deputy.
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Risk-Based CMC Review Paradigm
Multnomah County Health Department ►Essential Services ►FDA Food Standards ►PACE Tools for Food Program Excellence Lila Wickham March 17, 2004 ♣
Organizational Gaps in Reaching the “Desired State” Helen Winkle.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.
Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.
Health Overview Policy and Scrutiny Panel Update on Health Reform Proposals James Foster North Somerset Council.
United States Department of Agriculture Food Safety and Inspection Service 1 National Advisory Committee on Meat and Poultry Inspection August 8-9, 2007.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Presenter’s Name June 17, Directions for this Template  Use the Slide Master to make universal changes to the presentation, including inserting.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
FLOOD RISK MANAGEMENT The next steps. The National Technical Advisory Group On Flooding Issues An Overview and the Future.
1 Basis of the Proposed Tactical Plan for a QbD approach for Quality Control and Assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director,
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
CALIFORNIA’S AIR TOXICS PROGRAM: IMPROVEMENTS TO ASSESS HEALTH RISK Update to the Air Resources Board July 24, 2014 California Environmental Protection.
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
© G.K.Raju, Ph.D. Confidential FDA Manufacturing Subcommittee Meeting July 20, 2004 G.K. Raju, Ph.D. Executive Director, MIT/PHARMI Massachusetts Institute.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Research Needs to Support FDA Risk Communication Nancy M. Ostrove, Ph.D. Director for Risk Communication May 1, 2009.
FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration November.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
ICH Quality Topics Update
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS.
Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.
FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
PP 620: Public Policy and Health Administration Unit One Seminar Kris R. Foote, J.D., M.P.A., M.S.W. Kaplan University.
Total Quality Management Pharmaceuticals. MEDICINE/pharmaceuticals Medicine / Brand/ Product.
Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.
Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.
New Ecological Science Advice for Ecosystem Protection The EPA Science Advisory Board (SAB) Staff Office supports three external scientific advisory committees.
Principles of Good Governance
U.S. FDA Center for Devices and Radiological Health Update
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Pharmaceutical Quality in the 21st Century
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Quality System.
Research Program Strategic Plan
Support for the AASHTO Committee on Planning (COP) and its Subcommittees in Responding to the AASHTO Strategic Plan Prepared for NCHRP 8-36, TASK 138.
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Finance & Planning Committee of the San Francisco Health Commission
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization of Topics for Discussion

Subcommittee Work Planning This afternoon –“Desired State” outlined by FDA Does this reflect a “shared vision” for the future? –Identify and prioritize topics for discussion –Recommend a format and background information FDA should prepare for discussion of identified topics

Subcommittee Work Planing Tomorrow –Update on current activities PAT Initiative and its role in the Drug Quality System for the 21st Century Comparability Protocols as tool for continuous improvement A perspective on risk analysis –Committee discussion on the relationship between process understanding, change management, and risk to quality –Update on aseptic processing guidance

A Drug Quality System for the 21 st Century: Objectives [1] Risk Management [2] Quality System [3] Recognize and encourage scientific advancement and innovation (continuous improvement) [4] Review & Inspection programs are coordinated, synergistic, and consistent [5] Effective and efficient utilization of FDA and (industry) resources

Begin with the end in mind…. The “Desired State” for Pharmaceutical Manufacturing and Associated Regulatory Processes in the 21st Century

Defining the “desired state” As we move forward with this initiative it is essential to define what we wish to achieve –What should be the “desired state” of pharmaceutical manufacturing and associated regulatory policies in the 21 st Century? A shared vision to guide further evolution of this initiative Enroll all stakeholders in this journey to better serve the patients Highlight, for the academic and research community, the scientific needs in pharmaceutical engineering

Approach We Use Must... Strengthen the public health protection achieved by FDA’s regulation of drug product manufacturing Not interfere with strong enforcement of the existing regulatory requirements Be risk based Be science based –(Win Win)

Science Provides a Win Win Approach Pharmaceutical manufacturing is evolving from an art form to one that is now science and engineering based. Effectively using this knowledge in regulatory decisions in establishing specifications and evaluating manufacturing processes can substantially improve the efficiency of both manufacturing and regulatory processes. This initiative is designed to do just that through an integrated systems approach to product quality regulation founded on sound science and engineering principles for assessing and mitigating risks of poor product and process quality in the context of the intended use of pharmaceutical products.

Desired State  Product quality and performance achieved and assured by design of effective and efficient manufacturing processes  Product specifications based on mechanistic understanding of how formulation and process factors impact product performance  Continuous "real time" assurance of quality

Desired State  Regulatory policies tailored to recognize the level of scientific knowledge supporting product applications, process validation, and process capability  Risk based regulatory scrutiny relate to the:  level of scientific understanding of how formulation and manufacturing process factors affect product quality and performance, and  the capability of process control strategies to prevent or mitigate risk of producing a poor quality product

Shared Vision for the future? FDA articulated the “desired state” based on discussions at several advisory committees (ACPS-PAT and FDA Sci. Board) Presented it at several public workshops and meetings We believe it now represents a “shared vision” of the pharmaceutical community Does the subcommittee agree?

Topics and Priorities Definition of “Quality” and “Risk” Risk models and management approaches Manufacturing science and process understanding –Process understanding and control strategies for mitigating “risk” –Process validation and capability

Topics and Priorities (Cont.) Manufacturing science and process understanding (Cont.) –Continuous improvement Use of prior knowledge (e.g., development) for risk mitigation and justification for less burdensome reporting (e.g., “Make Your Own SUPAC”) Design of experiments and failure mode analysis for assessing and mitigating risk –Specifications and in-process controls interim and final specifications risk and mechanism based approaches

Subcommittee Discussions Additional Background Information –Summary Reports from the April 2003 FDA/PQRI Workshop Subcommittee membership reflects diverse backgrounds. It will help FDA and other subcommittee members if each member first shares their individual perspectives on the initiative and the proposed topics and challenges they believe FDA will need to address

Subcommittee Discussions Subcommittee discussions and recommendations on the list of proposed topics for discussion –Objectives of these discussions will range from addressing specific questions posed by FDA working groups to broader discussion of FDA proposals –These recommendations will be shared with FDA working groups